@article{c5dcd21d964f4abdb7c833e358acdc33,
title = "Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades",
abstract = "With the Food and Drug Administration approval of 9 agents for different acute myeloid leukemia (AML) indications, the prognosis and management of AML is evolving rapidly. Herein, we review the important milestones in the history of AML research and therapy, discuss insights regarding prognostic assessment and prediction of treatment outcome, detail practical supportive care measures, and summarize the current treatment landscape and areas of evolving research.",
keywords = "AML, Biology, Prognosis, Targeted therapy, Therapy",
author = "Kantarjian, {Hagop M.} and Short, {Nicholas J.} and Fathi, {Amir T.} and Guido Marcucci and Farhad Ravandi and Martin Tallman and Wang, {Eunice S.} and Wei, {Andrew H.}",
note = "Funding Information: This work is supported in part by the MD Anderson Cancer Center Leukemia SPORE CA100632, the Cancer Center Support Grant P30CA016672, and the Charif Souki Cancer Research Grant; A.H.W. acknowledges support from LLS SCOR (Strasser), Medical Research Future Fund of Australia. N.J.S. is supported by the K12 Paul Calabresi Clinical Oncology Scholar Award and the American Society of Hematology Junior Faculty Scholar Award in Clinical Research. Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",
year = "2021",
month = sep,
doi = "10.1016/j.clml.2021.05.016",
language = "English (US)",
volume = "21",
pages = "580--597",
journal = "Clinical Lymphoma",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "9",
}
